Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires.
Share this article
Corporate
Score 85
Bullish
Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires
Mar 25, 2026 13:39 UTC
MRK, PFE, VRTX, ABBV
Short term
Related Articles
Score 65
Bullish
Neoclouds: new class of specialised cloud providers entering AI infrastructure scene
Mar 25, 15:55
Score 45
Bearish
Meta layoffs reportedly imminent as staff work from home
Mar 25, 15:50
Score 65
Bearish
Why Merck Might Have A Fight On Its Hands With Its $6.7 Billion Takeover Of Terns
Mar 25, 15:47
Score 35
Bearish
FuboTV Slumps 14% After Reverse Stock Split: Is the Streaming Underdog Running Out of Options?
Mar 25, 15:45
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.